Post-transplantation diabetes mellitus

Česká verzia

Authors: Zuzana Mesárošová ¹; Ivana Dedinská ^2,3; Ubomír Skladaný ¹
Authors place of work: II. interná klinika SZU a FNsP F. D. Roosevelta v Banskej Bystrici ¹; Transplantačno-nefrologické oddelenie UNM, Martin ²; I. interná klinika JLF UK a UNM, Martin ³
Published in the journal: Forum Diab 2024; 13(2): 73-78
Category: Review Article

Summary

With the development of immunosuppressive regimens and surgical techniques, the survival of patients after solid organ transplantation (Tx) has improved, resulting in an increase in the development of metabolic complications. Post-transplant diabetes mellitus (PTDM) is a serious and frequent metabolic complication after solid organ Tx. In addition to the typical risk factors that contribute to the development of diabetes mellitus, factors associated with Tx and subsequent treatment play a significant role in PTDM. The disease is associated with the development of complications and thus increased cost of treatment for the patient. Identification of at-risk individuals, prevention of disease development, early diagnosis if PTDM develops, and subsequent optimal treatment help to improve the quality and length of life of transplanted patients.

Keywords:

immunosuppressive treatment – post-transplant diabetes mellitus (PTDM) – transplantation (Tx)

Zdroje

Stralz TE. Experience in renal transplantation. Saunders: Philadelphia-London 1964: 262–283.

Davidson J, Wilkinson A, Dantal J et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation 75(10): 3–24. Dostupné z DOI: <http://dx.doi.org/10.1097/01.TP.0000069952.49242.3E>.

Shariff A, Hecking M, de Vries AP et al. Proceedings From an International Consensus Meeting on Posttransplantation Diabetes Mellitus: Recommendations and Future Directions. Am J Transplant 2014; 14(9): 1992–2000. Dostupné z DOI: <http://dx.doi.org/10.1111/ajt.12850>.

Maskey R. New-Onset Diabetes after Transplant (NODAT). Journal of Diabetes Reasearch and Therapy 2015; 1(1). Dostupné z DOI: <doi.org/10.16966/2380–5544.105>.

Laecke S, Desideri F, Geerts A et al. Hypomagnesemia and the Risk of New-Onset Diabetes after Liver Transplantation. Liver Transpl 2010; 16(11): 1278–1287. Dostupné z DOI: <http://dx.doi.org/10.1002/lt.22146>.

Jenssen T, Hartmann A. Post-transplant diabetes mellitus in patients with solid organ transplants. Nat Rev Endocrinol 2019; 15(3): 172–188. Dostupné z DOI: <http://dx.doi.org/10.1038/s41574–018–0137–7>.

Pham PT, Pham MT, Pham SV et al. New onset diabetes after transplantation (NODAT): an overview. Diabetes Metab Syndr Obes 2011; 4: 175–86. Dostupné z DOI: <http://dx.doi.org/10.2147/DMSO.S19027>.

Pirsch J, Henning AK, First MR et al. New-onset diabetes after transplantation: results from a double-blind early corticosteroid withdrawal trial. Am J Transplant 2015; 15(7): 1982–1990. Dostupné z DOI: <http://dx.doi.org/10.1111/ajt.13247>.

Heit J, Apelqvist AA, Gu X et al. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature 2006; 443(7109): 345–349. <http://dx.doi.org/10.1038/nature05097>.

Peláez-Jaramillo M, Cárdenas-Mojica A, Gaete P et al. Post-liver Transplantation diabetes mellitus: A Review of Relevance and Approach to Treatment. Diabetes Ther 2018; 9(2): 521–543. Dostupné z DOI: <http://dx.doi.org/10.1007/s13300–018–0374–8>.

Vincenti F, Tuncer M, Castagneto M et al. Prospective, Multicenter, Randomized Trial to Compare Incidence of New-Onset Diabetes Mellitus and Glucose Metabolism in Patients Receiving Cyclosporine Microemulsion versus Tacrolimus after DeNovo Kidney Transplantation. Transplant Proc 2005; 37(2): 1001–1004. Dostupné z DOI: <http://dx.doi.org/10.1016/j.transproceed.2004.12.017>.

Maes B, Kuypers D, Messiaen T et al. Posttransplant diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation 2001; 72(10): 1655–1661. Dostupné z DOI: <http://dx.doi.org/10.1097/00007890–200111270–00014>.

Teutonico A, Schena P, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005; 16(10): 3128–3135. Dostupné z DOI: <http://dx.doi.org/10.1681/ASN.2005050487>.

Jessen T, Hartmann A. Post-transplat diabetes mellitus in patients with solid organ transplants. Nat Rev Endocrinol 2019; 15(3): 172–188. Dostupné z DOI: <http://dx.doi.org/10.1038/s41574–018–0137–7>.

Lea-Henry TN, Baird-Gunning J, Petzel E et al. Medication management on sick days. Aust Prescr 2017; 40(5): 168–173. Dostupné z DOI: <http://dx.doi.org/10.18773/austprescr.2017.057>.

Ammori J, Sigakis M, Englesbe MJ et al. Effect of intraoperative hyperglycemia during liver transplantation. J Surg Res 2007; 140(2): 227–233. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jss.2007.02.019>.

Jenssen T, Hartmann A. Emerging treatments for post-transplantation diabetes mellitus. Nat Rev Nephrol Advance 2015; 11(8): 465–477. Dostupné z DOI: <http://dx.doi.org/10.1038/nrneph.2015.59>.

Ahmed A, Keeffe EB. Current Indication and Contraindications for liver transplant. Clin Liver Dis 2007; 11(2): 227–247. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cld.2007.04.008>.

Everson T, Terrault NA, Lok AS et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrenceof hepatitis C after liver transplantation. Hepatology 2013; 57(5): 1752–1762. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.25976>.

Donadon V, Balbi M, Dal Mas M et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic lover disease. Liver Int 2010; 30(5): 750–758. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1478–3231.2010.02223.x>.

Stephen J, Anderson-Haag TL, Gustafson S et al. Metformin use in kidney transplant recipients in the United States: an observational study. Am J Nephrol 2014; 40(6): 546–553. Dostupné z DOI: <http://dx.doi.org/10.1159/000370034>.

Vest LS, Koraishy FM, Zhang Z et al. Metformin use in the first year after kidney transplant, correlates and associated outcomes in diabetic transplant recipients: a retrospective analysis of integrated registry and pharmacy claims data. Clin Transplant 2018; 32(8): e13302. Dostupné z DOI: <http://dx.doi.org/10.1111/ctr.13302>.

Inkster B, Zammit NN, Frier BM. Drug-induced hypoglycaemia in type 2 diabetes. Expert Opin Drug Saf 2012; 11(4): 597–614. Dostupné z DOI: <http://dx.doi.org/10.1517/14740338.2012.694424>.

Cusi K, Orsak B, Bril F et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabtes mellitus: a randomized trial. Ann Intern Med 2016; 165(5): 305–315. Dostupné z DOI: <http://dx.doi.org/10.7326/M15–1774>.

Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American HEart Association and American Diabetes Association. Diabetes Care 2004; 27(1): 256–263. Dostupné z DOI: <http://dx.doi.org/10.2337/diacare.27.1.256>.

Bae J, Lee MJ, Choe EY et al. Effects of dipeptidyl peptidase-4 inhibitors on hyperglycemia and blood cyclosporine levels in renal transplant patients with diabetes: a pilot study. Endocrinol Metab (Seoul) 2016; 31(1): 161–167. Dostupné z DOI: <http://dx.doi.org/10.3803/EnM.2016.31.1.161>.

Marso SP, Bain SC, Consoli A et al. [SUSTAIN-6 Investigators]. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375(19): 1834–1844. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1607141>.

Hernandez AF, Green JB, Janmohamed S et al. [Harmony Outcomes committees and investigators]. Albiglutide and cardiovascular outcomes in patientswith type 2 diabtes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392(10157): 1519–1529. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(18)32261-X>.

Gerstein HC, Colhoun HM, Dagenais GR et al. REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): adouble-blind, randomised placebo-controlled trial. Lancet 2019; 394(10193): 121–130. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(19)31149–3>.

Gupta NA, Mells J, Dunham RM et al.Glucagon-like peptide-1receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010; 51(5): 1584–1592. Dostupné z DOI: <http://dx.doi.org/10.1002/hep.23569>.

Newsome PN, Buchholtz K, Cusi K et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatits. N Engl J Med 2021; 384(12): 1113–1124. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2028395>.

Hurren KM, Pinelli NR. Drug-drug interactions with glucagon-like peptide-1 receptor agonists. Ann Pharmacother 2012; 46(5): 710–717. Dostupné z DOI: <http://dx.doi.org/0.1345/aph.1Q583>.

Zinman B, Wanner C, Lachin JM et al. [EMPA-REG OUTCOME Invetigators]. Empagliflozin, Cardiovascular Outcomes and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>.

Neal B, Perkovic V, Mahaffey KW et al. [CANVAS Program Collaborative Group]. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377(7): 644–657. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1611925>.

Wiviott SD, Raz I, Bonaca MP et al. [DECLARE-TIMI 58 investigators]. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380(4): 347–357. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1812389>.

Cehic MG, Muir CA, Greenfield JR et al. Efficacy and Safety of Empagliflozin in the Management of Diabetes Mellitus in Heart Transplant Recipients. Transplant Direct 2019; 5(5): e450. Dostupné z DOI: <http://dx.doi.org/10.1097/TXD.0000000000000885>.